Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Jun 2011

Crespin Daniel J, Federspiel Jerome J, Biddle Andrea K, Jonas Daniel E, Rossi Joseph S

Abstract excerpt

BACKGROUND: Clopidogrel's effectiveness is likely reduced significantly for prevention of thrombotic events after acute coronary syndrome (ACS) in patients exhibiting a decreased ability to metabolize clopidogrel into its active form. A genetic mutation responsible for this reduced effectiveness is detectable by genotyping. Ticagrelor is not dependent on gene-based metabolic activation and demonstrated greater...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Adenosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Markov Chains

Share to Platelet Aggregation Inhibitors

Share to Secondary Prevention

Share to Ticagrelor

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 21669373
DOI: 10.1016/j.jval.2010.11.012
PMCID: PMC3384486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.PMID 21669373Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.Semantic proximity Read ↗

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.Semantic proximity Read ↗

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.Semantic proximity Read ↗

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.Semantic proximity Read ↗

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.